Find and Pitch Jounalists, Get Your Story Covered

Tags: Pheno Therapeutics MS candidate remyelination ursodiol therapy,UDCA treatment,PBC medication options,Ocaliva (obeticholic acid),second-line PBC treatments,cholestatic liver disease management,antimitochondrial antibody treatment,liver transplantation PBC,PBC symptom management,autoimmune liver disease therapy antibody therapy, B cells, drug development, immunotherapy, monoclonal antibodies

	Profile	Recent Articles on Subject
1	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments - 22 days ago A biotech’s race to tackle the most severe hepatitis - 3 months ago 2024 PharmaVoice 100s: Clinical Trial Pros - 4 months ago In a Duchenne market beset by problems, Capricor data marks a bright spot - 7 months ago Kyverna follows oncology’s CAR-T cell playbook for an ultra-rare autoimmune disorder - 8 months ago Black Diamond looks to outwit cancer mutations - 12 months ago
2	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Pheno Therapeutics granted trial authorisation for MS candidate - about 2 months ago European Commission grants orphan drug designation for Vivet’s VTX-806 - 6 months ago
3	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Denali Therapeutics spinout raises $200M as neuro company resets - about 2 months ago STAT+: Investors funnel $275 million into Paragon Therapeutics spinout - 11 months ago STAT+: Biotech FogPharma raises $145 million in anticipation of more clinical trials, pharma partnerships - about 1 year ago STAT+: Biotech launches with $82 million for Parkinson’s cell therapy - about 1 year ago STAT+: Startup BioAge raises $170 million Series D for Zepbound combination therapy - about 1 year ago STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - about 1 year ago STAT+: Biotech incubator Curie.Bio graduates its first startup - over 1 year ago STAT+: Startup launches with $245 million for twice yearly asthma treatment - over 1 year ago
4	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about menopause treatments, Novo plans for Wegovy in India, and more - 3 months ago STAT+: Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more - 4 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 4 months ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 4 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 8 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 10 months ago STAT+: Pharmalittle: We’re reading about Biocon eyeing weight loss drugs, Sanofi layoffs, and more - 11 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 11 months ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - about 1 year ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - about 1 year ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - about 1 year ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - about 1 year ago STAT+: Sanofi ends deal for a rare disease drug after FTC voices monopoly concerns - about 1 year ago STAT+: Pharmalittle: Bluebird’s sickle-cell screwups may prompt a sale; drugmakers raised prices on widely used meds without new clinical evidence - about 1 year ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - about 1 year ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - about 1 year ago STAT+: Pharmalittle: AbbVie buys Immunogen, maker of targeted cancer drugs; Novo sues two more compounders - over 1 year ago STAT+: Pharmalittle: U.K. approves world’s first CRISPR-based medicine; FDA to review pricey cancer drug lacking confirmatory data - over 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - over 1 year ago STAT+: Pharmalittle: Novo Nordisk sees “significantly” more Wegovy in the U.S. next year; U.S. pharma layoffs skyrocket - over 1 year ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - over 1 year ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - over 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago
5	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond - 3 months ago 2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers - 4 months ago 23andMe inches closes to cancer immunotherapy, guided by its genetic database - 7 months ago A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients - 7 months ago A biotech dousing ‘fires’ in the brain that plagued a bestselling author - 7 months ago A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill - 8 months ago Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters - 10 months ago Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps - about 1 year ago A biotech tackles drug discovery with transcription factor know-how - over 1 year ago The PharmaVoice 100: Rare disease warriors - over 1 year ago
6	Jason Mast STAT News Writing about science, medicine. ScienceMedicineBusiness	STAT+: Novartis buys gene therapy startup Kate Therapeutics, joining pursuit of muscular dystrophy treatment - 3 months ago STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal - about 1 year ago
7	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Versant enters obesity with new startup - 3 months ago The biotech news you need to read today - 4 months ago
8	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	2024 PharmaVoice 100s: Rare Disease Warriors - 4 months ago Pharma’s ‘it’ therapy — a new drug class gaining steam - 6 months ago After Vyvanse patent loss, Takeda’s neuroscience division looks to enter a new era - 10 months ago Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D - 12 months ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - about 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago Red Jacket: Helen Sabzevari, an immunotherapy pioneer - over 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago
9	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Grants Orphan Drug Designation to PPL-002 for the Treatment of Danon Disease - 5 months ago FDA Grants Orphan Drug Designation to PT217 for Neuroendocrine Carcinoma - 7 months ago
10	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Cancer Biotech Repare Therapeutics Restructures to Focus on Clinical-Stage Pipeline - 6 months ago Otsuka Commits $800M in M&A Deal Bringing a Phase 3-Ready Metabolic Disorder Drug - 7 months ago

Journalists covering Pheno Therapeutics